SCHEMBL1950469

SCHEMBL1950469

COCC(=O)N1CCc2cc(NCc3ccc(Cl)cc3)ccc21

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
DRD4 P21917 4/20 0.50
DRD2 P14416 3/20 0.50
PTPN11 Q06124 1/20 0.49
THRB P10828 4/20 0.48
MAPT P10636 3/20 0.48
LMNA P02545 3/20 0.48
POLB P06746 2/20 0.48
HSP90AA1 P07900 1/20 0.47
HDAC8 Q9BY41 1/20 0.47
HDAC6 Q9UBN7 1/20 0.47
TP53 P04637 3/20 0.46
NOTUM Q6P988 1/20 0.46
TRIM24 O15164 1/20 0.46
IDO1 P14902 1/20 0.45
KCNH2 Q12809 1/20 0.45
AVPR2 P30518 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1948375 0.91 DRD2 (0.51) DRD4DRD2PTPN11THRBMAPT
SCHEMBL1950866 0.91 DRD2 (0.48) DRD4DRD2THRBMAPTLMNA
SCHEMBL1948510 0.86 NOTUM (0.64) DRD4DRD2THRBMAPTLMNA
SCHEMBL1950708 0.85 DRD4 (0.47) DRD4DRD2THRBLMNAPOLB
SCHEMBL20536797 0.84 MAPT (0.61) THRBMAPTLMNAPOLBTP53
SCHEMBL1948366 0.83 LMNA (0.47) DRD4DRD2THRBMAPTLMNA
SCHEMBL1950711 0.82 DRD2 (0.48) DRD4DRD2THRBMAPTLMNA
SCHEMBL1950717 0.82 KMT2A (0.49) MAPTLMNA
SCHEMBL2641013 0.81 PTPN11 (0.41) DRD4DRD2PTPN11THRBLMNA
SCHEMBL2641060 0.80 LMNA (0.44) DRD4DRD2THRBMAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2438055-B1 DIHYDROINDOLE AND TETRAHYDROISOQUINOLINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL INHIBITORS JAPAN TOBACCO INC (JP) 2018-10-24 EP claimed
US-8426442-B2 Compounds XENTION LTD (GB) 2013-04-23 US claimed
EP-2438055-A1 DIHYDROINDOLE AND TETRAHYDROISOQUINOLINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL INHIBITORS Xention Limited (GB) 2012-04-11 EP claimed
WO-2010139967-A1 DIHYDROINDOLE AND TETRAHYDROISOQUINOLINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL INHIBITORS XENTION LIMITED (GB) 2010-12-09 WO claimed
EP-2438055-B1 DIHYDROINDOLE AND TETRAHYDROISOQUINOLINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL INHIBITORS JAPAN TOBACCO INC (JP) 2018-10-24 EP disclosed
US-8426442-B2 Compounds XENTION LTD (GB) 2013-04-23 US disclosed
US-20110136860-A1 Compounds XENTION LTD. (GB) 2011-06-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110136860-A1 Compounds NR3C2, NR5A1, NR0B2 DRD4 739/4885DRD2 385/4885PTPN11 1418/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.